Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TST 003

Next Previous
Drug Profile

TST 003

Alternative Names: TST-003

Latest Information Update: 02 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Transcenta Holding
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Bone morphogenetic protein inhibitors; Epithelial-Mesenchymal transition inhibitors; Signal transduction pathway stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 29 Aug 2024 Transcenta Therapeutics completes enrolment in the phase I/II trial in Solid tumours (Monotherapy, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in USA and China (IV) (NCT05731271)
  • 28 May 2024 No recent reports of development identified for preclinical development in Solid-tumours in China (Parenteral)
  • 05 Apr 2024 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top